Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

The new device, the spinal cord stimulator, can be placed under the injury site via a simple injection, which distinguishes it from conventional stimulators, which are large and must be placed further ...

After hours: March 10 at 4:02:14 PM EDT Loading Chart for NVRO ...

Spinal Cord is a specialised, international journal that has been publishing spinal cord related manuscripts since 1963. It appears monthly, online and in print, and accepts contributions on ...

The word "myelopathy" means a problem with the spinal cord, which can lead to numbness, weakness, dysautonomia (group of conditions causing problems with involuntary movements), and more. There are ...

a responsive and personalized pain management platform that powers the HFX iQ spinal cord stimulation (SCS) system. In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system ...

meaning Nevro’s full-year guidance for 2025 dropped from $435-445m to $400m-$405m. Boston Scientific’s Wavewriter spinal cord stimulator systems, for example, gained access to a wider market ...